Company profile

Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Privately held: no public share price (Hangzhou, China-based tumor-immunotherapy biotech (bifunctional antibody/CAR-T platforms), established 2018, with subsidiary Tinova (Shanghai). No public listing found. Source: company site en.novatim-zj.com, Synapse/Citeline company profile. Sources: https://clinicaltrials.gov/study/NCT06223646 Entity resolved by asset-pipeline-v2.)

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
KQ-2003
Phase 2
BCMA / CD19Cell therapy
Multiple Myeloma

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.